Brain and Central Nervous System Tumors
Conditions
Keywords
adult anaplastic oligodendroglioma, adult oligodendroglioma, adult anaplastic astrocytoma, adult giant cell glioblastoma, adult gliosarcoma, recurrent adult brain tumor, adult brain stem glioma, adult mixed glioma, adult glioblastoma, adult pilocytic astrocytoma, adult diffuse astrocytoma, adult anaplastic ependymoma, adult ependymoma, adult myxopapillary ependymoma, adult subependymoma, adult pineal gland astrocytoma, adult subependymal giant cell astrocytoma
Brief summary
RATIONALE: Collecting samples of tumor tissue and blood from patients with cancer to study in the laboratory may help doctors learn how patients respond to treatment. PURPOSE: This clinical trial is looking at tumor tissue samples from patients receiving imatinib mesylate for malignant glioma to see how much imatinib mesylate is found in the tumor tissue.
Detailed description
OBJECTIVES: Primary * Determine the efficacy, of imatinib mesylate, in terms of achieving a therapeutic tumor:plasma concentration ratio, in patients with primary malignant glioma. Secondary * Correlate tumor grade (low vs high) and/or tumor enhancement on MRI with tumor concentration of this drug in these patients., OUTLINE: Patients receive oral imatinib mesylate once daily for 7-12 days. Patients then undergo surgical resection. Blood and tissue samples are collected at the time of surgery and analyzed for imatinib mesylate concentration. After completion of study treatment, patients are followed for 7 days. PROJECTED ACCRUAL: A total of 33 patients will be accrued for this study.
Interventions
DRUGimatinib mesylate
OTHERpharmacological study
PROCEDUREconventional surgery
Sponsors
National Cancer Institute (NCI)
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 120 Years
Healthy volunteers
No
Inclusion criteria
DISEASE CHARACTERISTICS: * Histologically confirmed malignant glioma of 1 of the following subtypes: * Low-grade glioma * Anaplastic astrocytoma * Anaplastic oligodendroglioma * Glioblastoma multiforme * Unifocal disease that is progressive or recurrent after prior radiotherapy and/or chemotherapy * Scheduled to undergo surgical resection * Able to undergo maximal surgical resection of tumor mass PATIENT CHARACTERISTICS: * Karnofsky performance status 70-100% * Mini Mental Status Exam ≥ 15 * Absolute neutrophil count ≥ 1,500/mm³ * Platelet count ≥ 100,000/mm³ * Creatinine ≥ 1.7 mg/dL * BUN ≤ 2 times upper limit of normal (ULN) * Transaminases ≤ 4 times ULN * Not pregnant or nursing * Fertile patients must use effective contraception during and for ≥ 1 month after completion of study treatment * No other medical illness that would preclude study treatment, including any of the following: * Serious infection * Uncontrolled hypertension * Unstable angina pectoris * Uncontrolled cardiac dysrhythmia PRIOR CONCURRENT THERAPY: * See Disease Characteristics * Recovered from all prior therapy * At least 4 weeks since prior investigational drugs * No more than 1 prior chemotherapy regimen * No concurrent chemotherapy, biologic therapy, or radiotherapy * No concurrent medications that may interact with imatinib mesylate or interfere with hepatic cytochrome P450 system
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Tumor:plasma concentration ratio of imatinib mesylate | 2 weeks |
Countries
United States
Outcome results
None listed